Chih‐Hsien Wang

机构：National Taiwan University Hospital · ORCID：0000-0003-3214-6867

发表论文 319 篇 · 总被引 6608 次 · h-index 37

代表论文

• Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial (2023 · The Lancet · 被引 301)
• Advances in the molecular mechanisms of statins in regulating endothelial nitric oxide bioavailability: Interlocking biology between eNOS activity and L-arginine metabolism (2024 · Biomedicine & Pharmacotherapy · 被引 71)
• Apigenin targets fetuin-A to ameliorate obesity-induced insulin resistance (2024 · International Journal of Biological Sciences · 被引 29)
• Association of endothelial dysfunction and peripheral arterial disease with sarcopenia in chronic kidney disease (2024 · Journal of Cachexia Sarcopenia and Muscle · 被引 21)
• Novel equations incorporating the sarcopenia index based on serum creatinine and cystatin C to predict appendicular skeletal muscle mass in patients with nondialysis CKD (2024 · Clinical Nutrition · 被引 13)
• Identification of a new genetic locus associated with atrial fibrillation in the Taiwanese population by genome-wide and transcriptome-wide association studies (2025 · EP Europace · 被引 10)